

Advantage Growth Fund exits Scriptswitch generating stellar return for its investors

Midven is delighted to announce the sale of Scriptwitch to United Health UK (“UHUK”), part of United Health Group Inc, a US quoted global health and wellbeing company. The transaction value is undisclosed, however Midven’s Advantage Growth Fund has exited in full.

ScriptSwitch is the leading provider of software designed to support GPs with patient safety information, drug switch recommendations and dosage optimisation information at the point of prescribing.

Its success in boosting patient safety as well as driving cost savings on prescribed drugs has meant that it is now used by more than 60% of Primary Care Organisations in the UK. Annualised savings to the NHS as a result of decisions made by GPs, supported by ScriptSwitch are set to exceed £20 million.

Midven invested in Scriptswitch in 2003 through its Advantage Growth Fund at a time when the Company was still largely focused on product development, had minimal sales and was operating without a fully fledged management team. Midven worked closely with the Company during this formative years and the number of patients with access to the Scriptswitch service has grown significantly.

Tony Stott, CEO of Midven commented “This transaction is evidence that returns can be made from investing in start-up technology businesses and demonstrates that when managed appropriately by an experienced and focused fund manager the Government backed Regional Venture Capital Fund model should generate good returns for its investors.”

The sale marks the end of a very successful year for ScriptSwitch. In April 2009 the business was awarded a Queens Award for Enterprise in the Innovation category. More recently, Mike Washburn, CEO was announced as the BVCA (British Private Equity and Venture Capital Association) 'Venture Capital Backed CEO of the Year'.

Mike Washburn, comments:

“ Midven have supported the team in helping us develop and build the business over recent years. I’m looking forward to the next phase in our development, confident that we’ve built a robust and scalable business”.

EDITORS’ NOTES

Midven Limited is a privately owned company with a successful track record of investing in small and medium-sized enterprises in the Midlands. The funds it manages have invested in a wide variety of sectors, including software, biotechnology, healthcare, engineering, manufacturing and distribution.

The £17.5 million Advantage Growth Fund was launched in February 2003 by Advantage West Midlands to invest venture capital in small and medium sized companies in the West Midlands. Managed by Midven Limited, its investors include Barclays Bank, the Royal Bank of Scotland, HSBC, the European Investment Fund, local universities and the Department for Business, Innovation and Skills.